Liposome Targeting to Macrophages: Opportunities for Treatment of Infectious Diseases

  • Richard Kirsh
  • George Poste
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 202)


The central role played by cells of the mononuclear phagocyte system (MPS) such as alveolar macrophages, hepatic Kupffer cells, splenic and lymph node macrophages, tissue histiocytes and circulating blood monocytes in the complex host reaction to neoplastic and infectious diseases has attracted increasing attention during the past 10 years. This interest stems from the experimental studies illustrating that macrophages when appropriately activated* play a major role in host defense against tumors and infectious microorganisms in vivo and also display enhanced tumoricidal and microbicidal activity in vitro 1–3. These observations, coupled with the disappointing results obtained in both clinical and experimental studies with immunologically-specific therapeutic modalities mediated by T and B lymphocytes in cancer immunotherapy has led to a renewed interest in the functions of macrophages and NK cells. Additionally, there is needed a reappraisal of the potential therapeutic benefit of augmenting non-specific host defense mechanisms mediated by mononuclear phagocytes for adjunct therapy of neoplastic and infectious diseases.


Drug Carrier High Density Lipoprotein Mononuclear Phagocyte Cutaneous Leishmaniasis Mononuclear Phagocyte System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pick, E. (ed.), Lymphokines, Vol. 3, Academic Press, NY, (1981).Google Scholar
  2. 2.
    Poste, G., and Fidler, I.J., The pathogenesis of cancer metastasis, Nature, 283:139–146, (1980).PubMedCrossRefGoogle Scholar
  3. 3.
    Fidler, I.J., and Poste, G., Macrophase-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease, Springer Semin. Immunopathol., 5:161–174, (1982).PubMedCrossRefGoogle Scholar
  4. 4.
    Chirigos, M.A., Mitchell, M., Mastrangelo, M.J., Krim, M. (Eds.), Modulation of Cellular Immunity in Cancer by Immune Modifiers, Raven Press, NY, (1981).Google Scholar
  5. 5.
    Ehrlich, P., Collected Studies on Immunity, Reprinted, Wiley, NY, Vol. 2, pp. 442–447, (1906).Google Scholar
  6. 6.
    Gregoriadis, G., Sr., and Trouet, A. (Eds.), Targeting of Drugs, Plenum Press, NY, (1982).Google Scholar
  7. 7.
    Bruck, S.D. (Ed.), Controlled Drug Delivery, CRC, Boca Raton, (1982).Google Scholar
  8. 8.
    Gregoriadis, G., and Allison, A.C. (Eds.), Liposomes in Biological Systems, Wiley Interscience, NY, (1980).Google Scholar
  9. 9.
    Poste, G., and Kirsh, R., Site-specific (targeted) drug delivery in cancer therapy, Biotechnology. 1:869–878, (1983).CrossRefGoogle Scholar
  10. 10.
    Szoka, F., and Papahadjopoulos, D., Liposomes. Preparation and characterization, in Liposomes: From Physical Structure to Therapeutic Applications, C. G. Knight (Ed.), Elsevier, Amsterdam, pp. 51–82, (1981).Google Scholar
  11. 11.
    Hauser, H., Methods of preparation of lipid vesicles: assessment of their suitability for drug encapsulation, Trends Pharm. Sci., 3:274–277, (1982).CrossRefGoogle Scholar
  12. 12.
    Leserman, L.D., Machy, P., Pevaux, C., and Barbet, J., Antibody-bearing liposomes: targeting in vivo. Biol. Cell, 47:111–116, (1983).Google Scholar
  13. 13.
    Poste, G., Liposome targeting invivo: problems and opportunities, Biol. Cell. 47:19–30, (1983).Google Scholar
  14. 14.
    Poste, G., Kirsh, R., and Koestler, T., The challenge of liposome targeting in vivo, in Liposome Technology, G. Gregoriadis (Ed.), CRC Press, Boca Raton, FLA, pp. 1–28, (1983).Google Scholar
  15. 15.
    Poste, G., Kirsh, R., Fogler, W.E., and Fidler, I.J., Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery, Cancer Res., 42:1412–1422, (1982).PubMedGoogle Scholar
  16. 16.
    Scherphof, G.L., Interaction of liposomes with biological fluids and fate of liposomes in vivo. in Liposome Methodology, L.D. Leserman and J. Barbet (Eds.), pp. 79–92, Inserm, Paris, (1982).Google Scholar
  17. 17.
    Altura, B.M., Reticuloendothelial cells and host defense.Google Scholar
  18. 18.
    Taylor, R.L., Hilliams, D.M., Craven, P.C., Graybill, J.R., Drutz, P.J., and Magee, N.E., Amphotericin B in liposomes; a novel therapy for histoplasmosis, Am. Rev. Respir. Dis 125:610–611 (1982).PubMedGoogle Scholar
  19. 19.
    New, R.R.C., Chance, M.L., and Heath, S., The treatment of experimental cutaneous leishmaniasis with liposome-entrapped Pentostam, Parasitol. 83:519–527 (1981).CrossRefGoogle Scholar
  20. 20.
    Lopez-Berestein, G., Mehta, R., Hopfer, R.L., Mills, K., Kasi, L., Mehta, K., Fainstein, V., Luna, M. Hersh, E.M., and Juliano, R., Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposomne-encapsulated amphotericin B, J. Infect. Dis. 5:939–945 (1983).CrossRefGoogle Scholar
  21. 21.
    Graybill, J.R., Craven, P.C., Taylor, R.L., Hilliams, P.M., and Magee, N.E., KTreatment of murine cryptococcosis with liposome associated amphotericin B, J. Infect. Dis. 145: 748–751 (1982).PubMedCrossRefGoogle Scholar
  22. 22.
    Fountain, M.H., Pees, C., and Schultz, R.P., Enhanced intracellular killing of Staphylococcus aureus by canine monocytes treted with liposome containing amikacin, gentamicin, kanamycin, and tobramycin, Current Microbiol. 6:373–376 (1981).CrossRefGoogle Scholar
  23. 23.
    Alving, C.R., and Steck, E.A., The use of liposome-encapsulated drugs in leishmaniasis, Trends Biochem. Sci. 4:N175–177 (1979).CrossRefGoogle Scholar
  24. 24.
    Pesiderio, J.V., and Campbell, S.G., Liposome-encapsulated cephalothin in the treatment of experimental murine salmonellosis, RES: Journal of the Reticuloendothelial Society 34:279–287 (1983).Google Scholar
  25. 25.
    Bodey, G.P., Fungal infections complicating acute leukemia, J. Chron. Dis. 19:667 (1966).PubMedCrossRefGoogle Scholar
  26. 26.
    Degregorio, M.W., Lee, N.M.F., Linker, C.A., Jacobs, R.A., and Ries, C.A., Fungal infections in patients with acute leukemia, Am. J. Med. 73:543–548 (1982).PubMedCrossRefGoogle Scholar
  27. 27.
    Louria, D.B., and Sen, P., Fungal infections with a particular focus on the compromised host, Del. Med. J. 54:11–19 (1982).PubMedGoogle Scholar
  28. 28.
    Alexander, P., and Evans, R., Endotoxin and double stranded RNA render macrophages cytotoxic, Nature New Biology 232:76–78 (1971).PubMedGoogle Scholar
  29. 29.
    Cleveland, R.P., Meltzer, M.S., and Zbar, B., Tumor cytotoxicity in vitro by macrophages from mice infected with Mycobacterium bovis strain BCG, J. Nat. Cancer Inst. 52:1887–1894 (1974).PubMedGoogle Scholar
  30. 30.
    Scott, M.T., In vivo cortisone sensitivity of nonspecific antitumor activity of Corynebacteria parvum activated mouse peritoneal macrophages, J. Nat. Cancer Inst. 54:789–792 (1975).PubMedGoogle Scholar
  31. 31.
    Sone, S., and Fidler, I.J., In situ activation of tumoricidal properties in rat alveolar macrophages and rejection of experimental lung metastases by intravenous injections of Nocardia rubra cell wall skeleton, Cancer Immunol. Immunother. 12:203–209 (1982).CrossRefGoogle Scholar
  32. 32.
    Lederer, E., Synthetic immunostimulants derived from the bacterial cell wall, J. Med. Chem. 23:819–825 (1980).PubMedCrossRefGoogle Scholar
  33. 33.
    Parant, M., Parant, F., Chedid, L., Yapo, A., Petit, J.F., and Lederer, L., Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse, Int. J. Immunopharmacol 1:35–41 (1979).PubMedCrossRefGoogle Scholar
  34. 34.
    Poste, G., Kirsh, R., and Fidler, I.J., Cell surface receptors for lymphokines, Cell Immunol 44:72–88 (1979).Google Scholar
  35. 35.
    Papermaster, B.N., Holterman, O.A., and Klein, E., Preliminary observations on tumor regressions induced by local administration of a lymphoid cell culture supernatant fraction in patients with cutaneous metastatic lesions, 5:31–35 (1976).Google Scholar
  36. 36.
    Fidler, I.J., and Raz, A., The induction of tumoricidal capacities in mouse and rat macrophages by lymphokines, in Pick, E. (Ed.), Lymphokines, Vol. 3, Academic Press, New York, pp. 345–364 (1981).Google Scholar
  37. 37.
    Poste, G., and Kirsh, R., Rapid decay of tumoricidal activity and loss of responsiveness to lymphokines in inflammatory macrophages, Cancer Res. 39:2582–2590 (1979).PubMedGoogle Scholar
  38. 38.
    Poste, G., The tumoricidal properties of inflammatory tissue macrophages and multinucleate giant cells, Am. J. Pathol 96:595–608 (1979).PubMedGoogle Scholar
  39. 39.
    Poste, G., and Fidler, I.J., Active non-specific immunotherapy of lung metastases by macrophage activating agents encapsulated in liposome, in Optimization of Drug Delivery, A. Benzon, Symposium No. 17, H. Bundgaard, A. Hansen, and H. Kofod (Eds.), Bundgaard, Copenhage, pp. 48–429 (1982).Google Scholar
  40. 40.
    Koff, W.C., Showalter, S.D., Seniff, D.A., and Hampar, B., Lysis of Herpesvirus-infected cells by macrophages activated with free or liposome-encapsulated lymphokine produced by a murine T cell hybridoma, Infection and Immunity 42:1067–1072 (1983).PubMedGoogle Scholar
  41. 41.
    Koff, W.C., Fidler, I.J,, Showalter, S.D., Chakrabarty, M.K., Hampar, B., Ceccorulli, L.M., and Kleinerman, E.S., Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells, Science 224:1007–1009 (1984).Google Scholar
  42. 42.
    Alving, C.R., and Richards, R.L., Immunological aspects of liposomes, in The Liposomes., M. Ostro, ed., M. Dekker, New York (In Press) (1983).Google Scholar
  43. 43.
    Federal Register, Food and Drug Administration, Proposed new drug, antibiotic and biologic drug product regulations, 48:26720–749 (June 9, 1983) (1983).Google Scholar
  44. 44.
    Juliano, R.L., Lopez-Berenstein, G., Mehta, R., Hopfer, R., Mehta, K., and Kasi, L., Pharmacokinetic and therapeutic consequences of liposomal drug delivery: fluorodeoxyuridine and amphotericin B as examples, Biol. Cell 47: 39–46 (1983).Google Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Richard Kirsh
    • 1
  • George Poste
    • 1
  1. 1.Smith Kline and French LaboratoriesPhiladelphiaUSA

Personalised recommendations